Stereotaxis and Catheter Precision Combine Robotic Navigation and Preoperative Arrhythmia Localization to Treat Cardiac Arrhy...
November 08 2019 - 9:00AM
Stereotaxis (NYSE American: STXS) and Catheter Precision today
announced the first patients have been successfully treated with
the integration of Catheter Precision’s VIVO™ arrhythmia
localization and Stereotaxis’ Robotic Magnetic Navigation
technologies.
VIVO uses information commonly collected prior to cardiac
procedures to identify the source of dangerously rapid heartbeats.
Anatomical information from preoperative CT or MRI images are
combined with electrical information from standard 12-lead
electrocardiograms to identify the source of arrhythmias in
patients suffering from Idiopathic Ventricular Tachycardia and
Premature Ventricular Contractions. The noninvasive preoperative
imaging supports the planning of efficient and successful cardiac
ablation procedures. The latest version of Stereotaxis software,
recently cleared for use in Europe and by the FDA, utilizes a
software interface that integrates VIVO images and allows
physicians to utilize them to guide therapy during robotic cardiac
ablation procedures. The first integrated procedures were
successfully conducted by Prof. Sabine Ernst at the Royal Brompton
Hospital in London, United Kingdom.
“Combining VIVO’s accuracy in preoperatively localizing
arrhythmias with the safety and precision of Robotic Magnetic
Navigation for delivering therapy allows for efficient, safe and
successful treatment of arrhythmias,” said Prof. Sabine Ernst. “The
integrated procedures worked well and provided an enhanced
workflow. The integration of leading diagnostic and therapeutic
technologies is important for patient care and the advancement of
electrophysiology.”
“Integration of intelligent guidance systems and state of the
art robotics may very well be the future of electrophysiological
procedures,” said Steve Adler, President and CEO of Catheter
Precision. “Thank you to Prof. Ernst, her team at the Royal
Brompton Hospital, and the staff at Stereotaxis and Catheter
Precision for pioneering this effort.”
“Stereotaxis is committed to advancing a robust open ecosystem
where physicians and patients benefit from the broad integration of
procedure data,” said David Fischel, CEO of Stereotaxis. “We are
excited to integrate with VIVO. Improved diagnostic information
within the robotic environment supports physicians in better
treating their patients and advances the digitization of
electrophysiology.”
About Catheter PrecisionCatheter Precision is
focused on developing novel technologies that provide patients,
physicians, and hospitals with new tools to improve the lives of
people suffering from cardiac arrhythmias. With offices in the
United States and Europe, Catheter Precision makes its innovative
devices available worldwide. For more information, please
visit www.catheterprecision.com.
About StereotaxisStereotaxis is the global
leader in innovative robotic technologies designed to enhance the
treatment of arrhythmias and perform endovascular procedures. Its
mission is the discovery, development and delivery of robotic
systems, instruments, and information solutions for the
interventional laboratory. These innovations help physicians
provide unsurpassed patient care with robotic precision and safety,
improved lab efficiency and productivity, and enhanced integration
of procedural information. Stereotaxis’ robotic technology has
received various regulatory clearances in the United States,
European Union, Japan, Canada, China, and elsewhere. For more
information, please visit www.stereotaxis.com.
This press release includes statements that may constitute
"forward-looking" statements, usually containing the words
"believe”, "estimate”, "project”, "expect" or similar expressions.
Forward-looking statements inherently involve risks and
uncertainties that could cause actual results to differ materially
from the forward-looking statements. Factors that would cause or
contribute to such differences include, but are not limited to, the
Company's ability to raise additional capital on a timely basis and
on terms that are acceptable, its ability to continue to manage
expenses and cash burn rate at sustainable levels, its ability to
continue to work with lenders to extend, repay or refinance
indebtedness, or to obtain additional financing, in either case on
acceptable terms, continued acceptance of the Company's products in
the marketplace, the effect of global economic conditions on the
ability and willingness of customers to purchase its systems and
the timing of such purchases, competitive factors, changes
resulting from healthcare reform in the United States, including
changes in government reimbursement procedures, dependence upon
third-party vendors, timing of regulatory approvals, and other
risks discussed in the Company's periodic and other filings with
the Securities and Exchange Commission. By making these
forward-looking statements, the Company undertakes no obligation to
update these statements for revisions or changes after the date of
this release. There can be no assurance that the Company will
recognize revenue related to its purchase orders and other
commitments in any particular period or at all because some of
these purchase orders and other commitments are subject to
contingencies that are outside of the Company's control. In
addition, these orders and commitments may be revised, modified,
delayed or canceled, either by their express terms, as a result of
negotiations, or by overall project changes or delays.
Stereotaxis: |
|
Catheter Precision: |
David Fischel |
|
Steve Adler |
Chairman and CEO |
|
President and CEO |
|
|
|
Kimberly Peery |
|
973-691-2000 |
Chief Financial Officer |
|
info@catheterprecision.com |
|
|
|
314-678-6100 |
|
|
investors@stereotaxis.com |
|
|
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Sep 2023 to Sep 2024